Protocol approach 2: gut-focused autoimmune support (BPC-157 plus KPV) Goal: Restore gut barrier integrity and reduce intestinal inflammation Components: BPC-157 : 200-300 mcg twice daily, orally or subcutaneously near the abdomen (promotes mucosal healing, angiogenesis) KPV: 200-500 mcg daily, orally (NF-kB inhibition, cytokine reduction, PepT1-mediated gut absorption) Rationale: For autoimmune conditions with significant gastrointestinal involvement, including IBD, celiac-associated inflammation, or any autoimmune condition complicated by leaky gut, this combination addresses both the physical barrier damage (BPC-157) and the inflammatory signaling (KPV)
It's a primary regulator of actin, a protein that is fundamental to cell structure, movement, and division
Houen et al., 2020), including a recently published large comprehensive survey of US military personnel (Bjornevik et al., 2022), that EBV exposure greatly increases the risk of MS, to the point that it might be a sine qua non for later MS development
No, neither peptide is approved for general therapeutic use
The peptide cost calculator can help estimate the ongoing expense of maintaining this dual-peptide protocol
This helps maintain the integrity of your ability to accurately calculate 5-Amino-1MQ dosage over time
